AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • August 1st, 2019 • Viela Bio, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 12th day of June, 2019, by and among Viela Bio, Inc., a Delaware corporation (the “Company”) and each of the stockholders of the Company listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • August 1st, 2019 • Viela Bio, Inc. • Pharmaceutical preparations
This License and Collaboration Agreement (the “Agreement”), dated as of the last signature hereunder (the “Effective Date”), is by and between Viela Bio, Inc., a company organized and existing under the laws of Delaware, United States of America (“Viela”), and Hansoh Pharmaceutical Group Company Limited, a company organized and existing under the laws of Cayman Islands (“Hansoh”). Viela and Hansoh are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
LICENSE AGREEMENTLicense Agreement • August 1st, 2019 • Viela Bio, Inc. • Pharmaceutical preparations • North Carolina
THIS LICENSE AGREEMENT made and entered into this 21st day of September, 2004 (“EFFECTIVE DATE”), by and between DUKE UNIVERSITY, a nonprofit educational and research institution organized under the laws of North Carolina (“DUKE”), having its principal office at Durham, North Carolina 27708, and Cellective Therapeutics, Inc., a corporation organized under the laws of Delaware (“COMPANY”), with its corporate headquarters and principal office at 4819 Emperor Boulevard, Suite 400, Durham, North Carolina 27703.
LICENSE AGREEMENT between SBI BIOTECH CO. LTD. and MEDIMMUNE, LLC. dated as of September 9, 2008License Agreement • August 1st, 2019 • Viela Bio, Inc. • Pharmaceutical preparations • New York
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
